In contrast to the pretreatment group, as well as previous work on PHD inhibitors in IBD care, this restorative treatment regimen (DSS, DPCA‐RT), better recapitulates clinical IBD therapies that are used to treat active disease.[23]. The gene discussed is PDC; the disease is inflammatory bowel disease.